A reliable AI workflow needs to preserve context: brand versus molecule : Ozempic and Wegovy are both semaglutide, but not the same market object single versus dual agonist : tirzepatide is not simply another semaglutide brand indication : diabetes, obesity, and cardiovascular risk reduction are different analytic frames funding status : PBS and private-pay populations can behave very differently time period : a 2023 shortage-period record is not equivalent to a 2026 post-shortage record source type : TGA, PBS, PBAC, company releases, media reporting, and clinical trials have different evidentiary roles The main AI risk is not that a model cannot summarise GLP-1 information
Mohammadi EN, Louwies T, Pietra C, Northrup SR, Meerveld BG-V
Supplements may be particularly useful for those with dietary restrictions, absorption issues or increased nutritional needs
As the drug has skyrocketed in popularity, the investment community has taken notice, and rightfully so given the implications that a miracle weight loss drug could have on the market and society at large
Our patients had good glycemic control at baseline, so their improvement in HbA1c while on treatment wasnt as dramatic as the population in the SUSTAIN-6 trial, explains Joo
180 The study included 35 GERD patients, all of whom had heartburn or dyspeptic symptoms and were referred from General Practitioners
